Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
about
Clinical Development of the E75 Vaccine in Breast CancerMetronomic Chemotherapy for Metastatic Breast Cancer – a Systematic Review of the LiteratureFirst-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Novel approaches to target HER2-positive breast cancer: trastuzumab emtansineMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItTargeting dormant micrometastases: rationale, evidence to date and clinical implicationsABC3 Consensus Commented from the Perspective of the German GuidelinesMechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancerBreast cancer brain metastases: the last frontierHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewThe La-Related Proteins, a Family with Connections to CancerNatHER: protocol for systematic evaluation of trends in survival among patients with HER2-positive advanced breast cancerDual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerReview on the Applications and Molecular Mechanisms of Xihuang Pill in Tumor TreatmentAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.CIViC databaseLung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.Overview of the CLEOPATRA Trial: Implications for Advanced PractitionersTargeted Therapies for Brain Metastases from Breast CancerNeratinib in HER-2-positive breast cancer: results to date and clinical usefulnessMolecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerRecent developments and translational aspects in targeted therapy for metastatic breast cancerResistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategiesErbB2 signaling at the crossing between heart failure and cancerDiagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation OncologyCombination therapeutics in complex diseasesAn Introduction to Survival Statistics: Kaplan-Meier AnalysisThe genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyondRecent advances in the medical treatment of breast cancerTwenty years of anti-HER2 therapy-associated cardiotoxicityEstrogen-Related Receptors in Breast Cancer and Prostate CancerCost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.Implementing Genome-Driven Oncology.Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.[Good Prognosis! Breast Cancer Update 2016].ABC3 Consensus: Assessment by a German Group of ExpertsAdjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.Use of big data in drug development for precision medicine.
P2860
Q26745440-0CBA78AC-1BC8-4288-8487-690579F8DF0DQ26745462-132940D0-30FF-4F68-AE2D-9D2742B24827Q26746081-37C34FDD-B14B-4D66-9056-EA9CB6E5C933Q26747729-A20837A8-17CE-4C8D-9D38-B5785511D92BQ26752780-13DA2B92-6999-46ED-8816-4B7442D8E329Q26765205-A80C845B-6F92-4D43-937B-EF80DE5A894EQ26768665-4FBFC04D-9DB2-4AC8-B926-1C9527D72FB9Q26772969-1382D1F9-22E9-45AC-8970-9C8B587CD1CDQ26775663-4884B482-60B1-4E2C-8D1B-A36D540EA934Q26777681-C3CE9663-3407-4D58-B2B5-9575100A0BF6Q26777733-31D56F22-1984-4459-BCE8-A0B133C439AAQ26778934-9CFE34EF-D103-4662-B96D-38FBE9A8B19BQ26782856-7AFD7E8D-B5E1-4D56-A211-F46555C62644Q26785612-1A0F8F33-6EDC-4303-9CE4-1EA0E7FF946CQ27009539-E7C8DC79-406C-49E1-BD93-98E7723C382FQ27343148-D5346903-BBD4-4232-93E3-9E348685C72CQ27612411-1F4F16EB-B503-4CE8-9A73-A92E36DC9EBAQ27853282-D48BAFC3-C788-42CE-80BD-9DA259B362E8Q28066819-7D5A9798-38C9-455B-958F-73D22AA527B5Q28068154-30749D5E-1B27-4F66-B9B5-B3E334693472Q28071303-F90DCCF5-B34C-48F7-BA06-5FB3C9341826Q28072513-E9E2A109-C0A1-46F4-81AB-A209ECDBCF97Q28072755-301093C0-4CB0-495B-9A83-B1D19CD23ECCQ28072897-7400A020-6C4E-474C-9C91-44C13C4B64B1Q28075244-41BDA7A1-B87F-4744-ACA0-8B16CFE17F44Q28076646-F5DEAB8A-816A-469E-91C8-1410254E1425Q28076891-0CC3186F-F962-4DF1-B41E-35BCF6C31320Q28077386-8B714B8B-5A44-4DBB-B4F4-B94A54F5CEE2Q28078788-4013C34A-98E4-4B6F-A8A2-51195EBD59E0Q28078951-F69E2AC6-C6BC-4FD3-B3A6-334C9B870171Q28079391-112181FB-8CF0-4B3F-B26D-309085426C9BQ28084030-1C40EE83-DFD4-4892-8CC2-73AE302C7AC0Q28267134-A7AF3A4F-76F9-4A6B-96CA-931E00620693Q30235979-54F4E309-4A67-49C2-8AFE-3F13B3C848E7Q30239901-3DACB625-DB53-4A16-869E-AEF08B96DD23Q30249775-A4CA628E-8DA5-4AC5-93EE-0BC7B726BB51Q30315301-1AA5AA47-572F-4696-9D68-88C476EE4336Q30758991-B4E45114-B24F-448E-94B7-0992CBA35A60Q30783484-F2FECD2A-69F9-41A7-9BA4-C049EFCD3D3CQ31115480-3927FAEE-CA77-4DAE-B023-CEE3AC8A052B
P2860
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
@ast
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
@en
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
@nl
type
label
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
@ast
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
@en
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
@nl
prefLabel
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
@ast
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
@en
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
@nl
P2093
P2860
P921
P3181
P356
P1476
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
@en
P2093
CLEOPATRA Study Group
Emma Clark
Eva Ciruelos
Graham Ross
Javier Cortés
Jean-Marc Ferrero
José Baselga
Jungsil Ro
Mario Campone
Mark C Benyunes
P2860
P304
P3181
P356
10.1056/NEJMOA1413513
P407
P577
2015-02-01T00:00:00Z